Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.71 |
| ▸ | RXRB | P28702 | 2/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.50 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27537578 | 0.88 | MCL1 (0.73) | MCL1MYCNR1H4FTOEDNRB | |
| SCHEMBL6033708 | 0.85 | MCL1 (0.56) | MCL1MYCNR1H4FTOLDHA | |
| SCHEMBL10024228 | 0.85 | MCL1 (0.53) | MCL1RXRBMYCRXRACAMKK2 | |
| SCHEMBL9414333 | 0.85 | MCL1 (0.53) | MCL1RXRBMYCRXRACAMKK2 | |
| SCHEMBL4651517 | 0.85 | MCL1 (0.65) | MCL1MYCNR1H4FTOEDNRB | |
| SCHEMBL10024266 | 0.85 | ACMSD (0.65) | MCL1RXRBRXRACAMKK2ACMSD | |
| SCHEMBL28789045 | 0.85 | MCL1 (0.65) | MCL1MYCNR1H4FTOEDNRB | |
| SCHEMBL1510071 | 0.85 | MCL1 (0.53) | MCL1RXRBMYCRXRACAMKK2 | |
| SCHEMBL7429140 | 0.84 | MCL1 (0.55) | MCL1RXRBMYCRXRACAMKK2 | |
| SCHEMBL13522888 | 0.83 | ACMSD (0.63) | MCL1RXRBRXRACAMKK2RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444225-B1 | PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK SERONO SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | FAS SECURED CREDITORS HOLDCO, LLC | 2012-04-05 | — | — | US | disclosed |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| EP-1390347-B1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACTIVITY | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1829861-A2 | Pyrrolidine ester derivatives active as oxytocin antagonists | Applied Research Systems ARS Holding N.V. (AN) | 2007-09-05 | — | — | EP | disclosed |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| US-7211601-B2 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-05-01 | — | — | US | disclosed |
| US-7189754-B2 | Pyrrolidine ester derivatives with oxytocin modulating activity | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2007-03-13 | — | — | US | disclosed |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDDING N.V. (NL) | 2006-10-12 | — | — | US | disclosed |
| US-7115639-B2 | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | MERCK SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040147511-A1 | Pyrrolidine ester derivatives with oxytocin modulating activity | MERCK SERONO SA (CH) | 2004-07-29 | — | — | US | disclosed |
| EP-1390347-A1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACTIVITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-02-25 | — | — | EP | disclosed |
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | MERCK SERONO SA (CH) | 2003-11-13 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-1268419-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| EP-1268418-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002074741-A1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACITVITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2002-09-26 | — | — | WO | disclosed |
| WO-2001074769-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001072705-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, CNR1, PRLHR | MCL1 4761/4885RXRB 934/4885MYC 4794/4885 |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, PRLHR, NR0B1 | MCL1 4747/4885RXRB 604/4885MYC 4828/4885 |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | OXTR, PRLHR, PGF | MCL1 4489/4885RXRB 3014/4885MYC 4857/4885 |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | OXTR, PRLHR, OXER1 | MCL1 4364/4885RXRB 3394/4885MYC 4840/4885 |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | OXTR, GPR6, CNR1 | MCL1 4341/4885RXRB 1654/4885MYC 4693/4885 |
| US-20040147511-A1 | Pyrrolidine ester derivatives with oxytocin modulating activity | OXTR, OPRL1, OPRD1 | MCL1 3573/4885RXRB 1423/4885MYC 4567/4885 |
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | LCAT, DGAT2, SOAT2 | MCL1 4030/4885RXRB 3198/4885MYC 4859/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | MCL1 1152/4885RXRB 842/4885MYC 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.